Lexicon Pharmaceuticals announces a license agreement exclusively with Novo Nordisk for LX9851 ()

Lexicon eligible to receive up to $ 1 billion in advance and development, regulations and sales payments, including $ 75 million in advance and short -term payments

Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and near-term milestone payments

Zur originalmeldung